Cabozantinib: A Review in Advanced Hepatocellular Carcinoma

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.

Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv238–55.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines)—hepatobiliary cancers [version 3.2018]. 2018. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf Accessed 1 Feb 2019.

Desai JR, Ochoa S, Prins PA, et al. Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol. 2017;8(2):243–55.

European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.

Raoul JL, Kudo M, Finn RS, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. Cancer Treat Rev. 2018;68:16–24.

Exelixis Inc. Cabometyx® (cabozantinib) tablets for oral use: US prescribing information. 2019. https://cabometyx.com/resources . Accessed 15 Jan 2019.

Ipsen Pharma. Cabometyx film-coated tablets: EU summary of product characteristics. 2019. https://www.ema.europa.eu . Accessed 4 Feb 2019.

Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308.

Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20(11):2959–70.

Nguyen L, Benrimoh N, Xie Y, et al. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs. 2016;27(7):669–78.

Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293–302.

Nguyen L, Holland J, Ramies DA, et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016;56(9):1130–40.

Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012–23.

Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.

Schoffski P, Gordon M, Smith DC, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017;86:296–304.

Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528–34.

Merle P, Rimassa L, Ryoo B, et al. Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC) [abstract no. O-011]. Ann Oncol. 2018;29(Suppl 5).

Meyer T, Baron A, Gordan J, et al. Outcomes in patients (pts) with hepatitis B virus (HBV) in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). [abstract no. 0-012]. In: International Liver Cancer Association Annual Meeting. 2018.

Blanc JF, Meyer T, Cheng AL, et al. Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) [abstract no. 703P plus poster]. Ann Oncol. 2018;29(Suppl 8).

Rimassa L, Cicin I, Blanc JF, et al. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) [abstract no. 4090]. J Clin Oncol. 2018;36(Suppl).

Kelley R, El-Khoueiry A, Meyer T, et al. Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). [abstract no. 702P plus poster]. Ann Oncol. 2018;29(Suppl 8).

Yau T, Cheng AL, Meyer T, et al. Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) [abstract no. 704P plus poster]. Ann Oncol. 2018;29(Suppl 8).

Kelley RK, Ryoo BY, Merle P, et al. Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). [abstract no. 4088]. J Clin Oncol. 2018;36(Suppl).

Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–97.

Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090–100.

Kudo M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma. Liver Cancer. 2018;7(2):123–33.

Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997;25(3):619–23.

Liu J, Wang K, Yan Z, et al. Axl expression stratifies patients with poor prognosis after hepatectomy for hepatocellular carcinoma. PLoS ONE. 2016;11(5):e0154767.

Bakouny Z, Assi T, El Rassy E, et al. Second-line treatments of advanced hepatocellular carcinoma: systematic review and network meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2018. https://doi.org/10.1097/mcg.0000000000001160 .

Roskell N, Gregory J, Wisniewski T, et al. Indirect treatment comparisons of nivolumab versus regorafenib, cabozantinib and best supportive care after treatment with sorafenib for hepatocellular carcinoma [poster no. PCN17]. In: ISPOR Europe conference. 2018.